Bempedoic Acid (ETC-1002) as an ACLY inhibitor has been approved by the Food and Drug Administration (FDA) for decreasing LDL-C levels in atherosclerotic cardiovascular disease, and has been applied to cancer therapeutic therapy32. Here, ACLY is linked to cancer.